BridgeBio Pharma ROA - Return on Assets 2018-2025 | BBIO

BridgeBio Pharma return on assets for the quarter ending March 31, 2025 was -81.84.

  • BridgeBio Pharma average return on assets for 2024 was -68.92, a 24.34% increase from 2023.
  • BridgeBio Pharma average return on assets for 2023 was -91.09, a 49.25% decline from 2022.
  • BridgeBio Pharma average return on assets for 2022 was -61.03, a 6.73% increase from 2021.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

BridgeBio Pharma ROA - Return on Assets 2018-2025 | BBIO

  • BridgeBio Pharma average return on assets for 2024 was -68.92, a 24.34% increase from 2023.
  • BridgeBio Pharma average return on assets for 2023 was -91.09, a 49.25% decline from 2022.
  • BridgeBio Pharma average return on assets for 2022 was -61.03, a 6.73% increase from 2021.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$15.5B
Dr Reddy's Laboratories (RDY)$11.4B
Bausch Health Cos (BHC)$1.9B
Supernus Pharmaceuticals (SUPN)$1.7B
Amphastar Pharmaceuticals (AMPH)$1.1B
Personalis (PSNL)$282M
Taysha Gene Therapies (TSHA)$254M
Assembly Biosciences (ASMB)$75M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$3M
Teligent (TLGT)$0M